EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Removal of basiliximab by plasmapheresis


, : Removal of basiliximab by plasmapheresis. American Journal of Kidney Diseases 37(1): E11-E11

Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 (IL-2) receptors. Given its expected volume of distribution (plasma volume), therapeutic plasmapheresis may be expected to lower serum Basiliximab levels. A 20-mg dose of Basiliximab was given before plasmapheresis. Blood and pheresis fluid samples were obtained to monitor Basiliximab levels. A total of three blood samples were drawn: the first was obtained 4 hours before, the second sample immediately before commencement, and the third 2 hours after cessation of plasmapheresis. A fourth sample was obtained from the removed plasma. There was an appreciable reduction in Basiliximab concentration levels after plasmapheresis. From the change in serum concentration after plasmapheresis, approximately 64.6% of circulating Basiliximab was removed. Plasmapheresis removes substantial amounts of Basiliximab. Therefore, supplemental Basiliximab should be given after plasmapheresis to maintain the desired duration of IL-2R saturation.


Accession: 047230853

PMID: 11136200

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Nojima, M.; Yoshimoto, T.; Nakao, A.; Itahana, R.; Kyo, M.; Hashimoto, M.; Shima, H., 2005: Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient. Basiliximab, a chimeric monoclonal antibody against the alpha chain of the interleukin-2 receptor (IL-2R) has been used in renal transplant patients. We monitored sequential blood concentrations of basiliximab in a patient who received a kidney tr...

Nakajima K.; Homma Y.; Matuda M.; Ishida K.; Yasumoto Y.; Mikami Y.; Nomoto H.; Araki G., 1988: Removal of anti acetylcholine receptor antibody by plasma exchange double filtration plasmapheresis and immunoadsorbent plasmapheresis. Oda, T (Ed ) Isao (International Society For Artificial Organs) Press Publication, No 312 Therapeutic Plasmapheresis; Seventh Symposium, Tokyo, Japan, June 5-6, 1987 Xii+515p Isao Press: Cleveland, Ohio, Usa Illus Paper 305-307

Araki G., 1987: Selectivity of ldl removal by double filtration and dextran sulfate cellulose column plasmapheresis and combination treatment by plasmapheresis and drugs for familial hypercholesterolemia. Oda, Thiokawa And N. Inoue. Isao (international Society For Artificial Organs) Press Publication, No. 311. Proceedings Of The First International Congress Of The World Apheresis Association: Therapeutic Plasmapheresis (vi); Tokyo, Japan, May . Xvi 810p. Isao Press: Cleveland, Ohio, Usa. Illus. Paper. 584-589

Homma Y.; Mikami Y.; Tamachi H.; Nakaya N.; Nakamura H.; Goto Y., 1987: Comparison of selectivity of ldl removal by double filtration and dextran sulfate cellulose column plasmapheresis and changes of subfractionated plasma lipoproteins after plasmapheresis in heterozygous familial hypercholesterolemia. The possibility of selective removal of low density lipoprotein (LDL) by double filtration (DF) and dextran-sulfate cellulose (DSC) column plasmapheresis in hypercholesterolemia and the acute recovery process of the subfractionated plasma lipoprot...

Homma, Y.; Mikami, Y.; Tamachi, H.; Nakaya, N.; Nakamura, H.; Goto, Y., 1987: Comparison of selectivity of LDL removal by double filtration and dextran-sulfate cellulose column plasmapheresis, and changes of subfractionated plasma lipoproteins after plasmapheresis in heterozygous familial hypercholesterolemia. The possibility of selective removal of low density lipoprotein (LDL) by double filtration (DF) and dextran-sulfate cellulose (DSC) column plasmapheresis in hypercholesterolemia and the acute recovery process of the subfractionated plasma lipoprot...

Chung, B.H.; Yun, J.T.; Ha, S.E.; Kim, J.I.; Moon, I.S.; Choi, B.S.; Park, C.W.; Kim, Y.S.; Yang, C.W., 2014: Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy. We investigated the effect of combined use of rituximab (RTX) and plasmapheresis (PP) pre-transplant on post-transplant infection. A total of 196 patients undergoing living-donor kidney transplantation at Seoul St. Mary's Hospital, all of who...

Martin Garcia, D.; Martin Gago, J.; Mendiluce, A.; Gordillo, R.; Bustamente, J., 2003: Tacrolimus-Basiliximab versus Cyclosporine-Basiliximab in renal transplantation "de novo": acute rejection and complications. Optimal immunosuppression is essential to maintain kidney allograft viability but minimizing toxicity is also fundamental. This article compares immunosuppressants, corticosteroids, cyclosporine, tacrolimus, and basiliximab, which are used in the...

Miyazaki M.; Sakagami K.; Matsuoka J.; Nishioka Y.; Matsunaga T.; Tsuboi K.; Ohsaki T.; Higaki K.; Fuchimoto S.; Orita K., 1985: Removal of immunosuppressive factors in serum of cancer patient by double filtration plasmapheresis simultaneous use of double filtration plasmapheresis and adsorbent. Artificial Organs 9(3): 311

Filipponi, F.; Callea, F.; Salizzoni, M.; Grazi, G.-Luca; Fassati, L.-Rainero; Rossi, M.; Risaliti, A.; Burra, P.; Agnes, S.; De-Carlis, L.; Valente, U.; Ferrara, R.; Pisati, R., 2004: Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab+steroids or basiliximab+placebo, in addition to cyclosporine and azathioprine. Background. Hepatitis C virus (HCV) recurrence in HCV+1 liver transplant recipients is almost inevitable and maybe promoted by immunosuppression. We compared the amount of liver damage with regard to usage of steroids and basiliximab. Methods. A t...

Filipponi, F.; Callea, F.; Salizzoni, M.; Grazi, G.Luca.; Fassati, L.Rainero.; Rossi, M.; Risaliti, A.; Burra, P.; Agnes, S.; D.C.rlis, L.; Valente, U.; Ferrara, R.; Pisati, R., 2004: Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Hepatitis C virus (HCV) recurrence in HCV+ liver transplant recipients is almost inevitable and may be promoted by immunosuppression. We compared the amount of liver damage with regard to usage of steroids and basiliximab. A total of 140 HCV+ adul...